Two novel compounds of vanadium and molybdenum with carnitine exhibiting potential pharmacological use

Galani, Angeliki; Tsitsias, Vassilis; Stellas, Dimitris; Psycharis, Vassilis; Raptopoulou, Catherine P.; Karaliota, Alexandra

doi:10.1016/j.jinorgbio.2014.10.004

Cited by 23 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…POM research represents an emerging field and especially bioactive POMs are getting more and more attractive due to their ability to interact with important enzymes like alkaline phosphatases, ecto-nucleotidases and ATPases and their potential to interfere with specific cellular processes, such as mitochondria respiration. 21 – 24 POMs like decavanadate or Keggin-type polyoxotungstates (POTs) and polyoxomolybdates are currently the focus of biological and biomedical research as they show promising antibacterial and antidiabetic activities, 21 , 22 , 24 – 28 whereas only few biological studies exist for other POM archetypes such as the Anderson structure. 29 …”

Section: Introductionmentioning

confidence: 99%

The P-type ATPase inhibiting potential of polyoxotungstates

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The P-type ATPase inhibiting potential of polyoxotungstates

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Petandis et al showed that a vanadium(V)-peroxido-betaine complex can inhibit TGFβ mediated epithelial-mesenchymal transition (EMT) and reduces the tumour cell migration in vitro [ 77 ]. There is published data indicating that decavanadate-based compounds can also reduce tumour cell viability in vitro and in vivo, however, it is not clear whether this is due to PTP inhibition or other effects of these compounds (discussed below) [ 4 , 112 , 113 ].…”

Section: Vanadium In Cancermentioning

confidence: 99%

Vanadium Compounds as PTP Inhibitors

Irving

Stoker

2017

Molecules

View full text Add to dashboard Cite

Phosphotyrosine signaling is regulated by the opposing actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). Here we discuss the potential of vanadium derivatives as PTP enzyme inhibitors and metallotherapeutics. We describe how vanadate in the V oxidized state is thought to inhibit PTPs, thus acting as a pan-inhibitor of this enzyme superfamily. We discuss recent developments in the biological and biochemical actions of more complex vanadium derivatives, including decavanadate and in particular the growing number of oxidovanadium compounds with organic ligands. Pre-clinical studies involving these compounds are discussed in the anti-diabetic and anti-cancer contexts. Although in many cases PTP inhibition has been implicated, it is also clear that many such compounds have further biochemical effects in cells. There also remain concerns surrounding off-target toxicities and long-term use of vanadium compounds in vivo in humans, hindering their progress through clinical trials. Despite these current misgivings, interest in these chemicals continues and many believe they could still have therapeutic potential. If so, we argue that this field would benefit from greater focus on improving the delivery and tissue targeting of vanadium compounds in order to minimize off-target toxicities. This may then harness their full therapeutic potential.

show abstract

“…The nanostructures were inoculated for three days with the cells. Then the cell viability was measured using a MTT assay described in Rubistein et al, 1990 andGalani et al, 2014.…”

Section: In Vitro Screeningmentioning

confidence: 99%

Design and development of multi-walled carbon nanotube-liposome drug delivery platforms

Pippa

Chronopoulos

Stellas

et al. 2017

International Journal of Pharmaceutics

Self Cite

View full text Add to dashboard Cite

The aim of this study is to design and develop delivery platforms made of liposomes and multi-walled carbon nanotubes (MWCNTs). We used different lipids with different main transition temperature (Tm) and differently functionalized MWCNTs with organic addends possessing either positive or negative charge. The phospholipids used for the formulations were 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (Tm=41°C) and L-α-phosphatidylcholine, hydrogenated Soy (HSPC) (Tm=53°C). By Differential Scanning Calorimetry (DSC), we studied the interaction between the DPPC and HSPC bilayers and MWCNTs. Liposome-MWCNTs delivery platforms prepared according to the protocol used in the literature. We used dynamic and electrophoretic light scattering in order to investigate the physicochemical characteristics of these mixed nanocarriers. The presence of MWCNTs causes alterations of the size of the conventional HSPC and DPPC liposomes. The ζ-potential values of mixed nanocarriers are near zero. This observation indicates the effective incorporation of MWCNTs into the lipid bilayer of liposomes. Fluorescence spectroscopy has been utilized to exact some qualitative information on the internal nanostructure and nanoenvironment of the lipid/carbon nanotube mixed structures. Finally, we conclude that we successfully prepare and completely characterize mixed nanocarriers composed of lipids and MWCNTs, with low toxicity as indicated by in vitro screening.

show abstract

Two novel compounds of vanadium and molybdenum with carnitine exhibiting potential pharmacological use

Cited by 23 publications

References 26 publications

The P-type ATPase inhibiting potential of polyoxotungstates

The P-type ATPase inhibiting potential of polyoxotungstates

Vanadium Compounds as PTP Inhibitors

Design and development of multi-walled carbon nanotube-liposome drug delivery platforms

Contact Info

Product

Resources

About